{
    "nct_id": "NCT03075072",
    "official_title": "Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation (SRS) in Patients With 5-20 Brain Metastases: A Phase III, Randomized Clinical Trial",
    "inclusion_criteria": "* Participants must have a biopsy proven solid malignancy with untreated (by radiation) intracranial lesions radiographically consistent with or pathologically proven to be brain metastases. Patients who have undergone prior systemic therapy are eligible\n* Five-twenty intracranial lesions must be present on MRI of the brain\n* Age 18-80 years at diagnosis of brain metastases\n* Karnofsky performance status of at least 70\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 80 Years",
    "exclusion_criteria": "* Participants who have undergone prior radiation for brain metastases.\n* Patients who have undergone resection of one or more brain metastases but who have not yet started adjuvant radiotherapy are eligible for the study\n* Participants who cannot undergo a brain MRI\n* Participants who cannot receive gadolinium (MRI contrast)\n* Participants with stage IV-V chronic kidney disease or end stage renal disease\n* Participants with widespread, definitive leptomeningeal disease\n* Participants with small cell lung cancer, lymphoma, or myeloma\n* Participants with a maximum tumor diameter exceeding 5 cm (if not resected)",
    "miscellaneous_criteria": ""
}